HDAC inhibitors such as entinostat and vorinostat reconfigure acetylation landscapes to reactivate cell-cycle and apoptotic networks suppressed in dormant cells, and potentiate DNMTi or cytotoxic effects in NSCLC models as well as in early clinical trials [171]. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.